PÚBLICO: "Infarmed approves first psychedelic for severe depression to be used in a hospital setting
Infarmed has approved public funding for the first drug containing ketamine, a psychedelic, to be used in hospital settings for adults with severe depression."
O Infarmed has approved o hospital hospital use of Spravato (scetamine) to treat adults with depression resistant, scheduling a significant significant in therapeutic therapeutic in Portugal, according to the article in Público.
A decision appliesto a patients who did not responded a at least at least three antidepressant antidepressants e who have contraindications or refusal à electroconvulsive therapy.
A ketamine, a pharmaceutical administered by nasal nasal route, offers an innovative innovative for severe severe cases of depression, and used under strict clinical monitoring.
At The Clinic of Change there is a treatment program with scetamine (Spravato) which you can consult here.
With this measure, Portugal strengthens o commitment to treatments treatments treatments scientific based treatments, offering new hope a patients with depression severe resistant.
Read the full story here.
